

**P&T Motion History**  
**Estrogens – Hormone Replacement Therapy**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
<b>Oral Estrogens</b> 17-beta estradiol estradiol valerate conjugated equine estrogen synthetic conjugated estrogen esterified estrogen estropipate conjugated estrogens/ bazedoxifene  <b>Transdermal Estrogens</b> 17-beta estradiol <ul style="list-style-type: none"> <li>• estradiol extended-release transdermal patch</li> <li>• estradiol 0.1% transdermal gel</li> </ul> estradiol transdermal spray  <b>Vaginal Products</b> 17-beta estradiol conjugated equine estrogen synthetic conjugated estrogens	After considering the evidence of safety, efficacy and special populations, I move that the drugs included in the following tables are efficacious and have no differences in efficacy identified in special populations for the indication of menopausal symptoms and can be subject to therapeutic interchange within route of administration and subclass (oral estrogens, oral estrogen-progestin combinations, transdermal estrogens, transdermal estrogen-progestin combinations, topical estrogen products) in the Washington preferred drug list. There is insufficient evidence available to compare the relative safety of the estrogen products at this time. The Committee recommends that practitioners prescribe the lowest effective dose for shortest duration of treatment for the particular estrogen product prescribed.	December 19, 2018	Yes Lee Chew	Yes Flatebo Park	Passed unanimous
		April 19, 2017	Yes Johnson Sanderson	Yes Johnson Figuroa	Passed unanimous